Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant609 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03420508 | Treating Patients With Melanoma and ALK Alterations With Ensartinib | active not recruiting | Phase 2 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05661955 | A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors. | active not recruiting | Phase 1 / Phase 2 | 113 | BeiGeneINDUSTRY | 1 | May 11, 2026 |
| clinicaltrials |
| NCT06697301 | Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. | recruiting | Phase 2 / Phase 3 | 740 | Eikon TherapeuticsINDUSTRY | 24 | May 8, 2026 | clinicaltrials |
| NCT04728633 | Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases | active not recruiting | Phase 2 | 28 | Thomas Jefferson UniversityOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04902040 | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | terminated | Phase 1 / Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT06151847 | Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma | completed | Phase 2 | 11 | University of Kansas Medical CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT06413680 | A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body(BrILliance) | recruiting | Phase 1 / Phase 2 | 240 | Regeneron PharmaceuticalsINDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT01416831 | Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.(SBRT/IL-2) | active not recruiting | Phase 2 | 44 | Providence Health & ServicesOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT02562625 | Trial of Pembrolizumab and Radiotherapy in Melanoma(PERM) | terminated | Phase 2 | 17 | Royal Marsden NHS Foundation TrustOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04207086 | A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma(Neo PeLe) | active not recruiting | Phase 2 | 21 | Melanoma Institute AustraliaOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05187884 | Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma(NADOM) | completed | Phase 2 | 15 | St Vincent's Hospital, SydneyOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06624644 | A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma | recruiting | Phase 2 / Phase 3 | 135 | Linnaeus Therapeutics, Inc.INDUSTRY | 1 | Apr 22, 2026 | clinicaltrials |
| NCT01604889 | A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 50 | Incyte CorporationINDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07288203 | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma | active not recruiting | Phase 2 | 100 | Iovance Biotherapeutics, Inc.INDUSTRY | 4 | Apr 20, 2026 | clinicaltrials |
| NCT02713269 | Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord | active not recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05026983 | Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases | recruiting | Phase 2 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06708663 | HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 124 | Hangzhou Hanx Biopharmaceuticals, Ltd.INDUSTRY | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07223424 | Patient Preference for Subcutaneous vs. Intravenous Immune Therapy(PSI-Immune) | recruiting | Phase 2 | 880 | Diwakar DavarOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT02656706 | Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma | active not recruiting | Phase 2 | 22 | Brown UniversityOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05423262 | A Study of TRK-950 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 49 | Toray Industries, IncINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06362369 | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | recruiting | Phase 1 / Phase 2 | 126 | 7 Hills Pharma, LLCINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06099782 | A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) | active not recruiting | Phase 2 | 147 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Apr 8, 2026 | clinicaltrials |
| NCT07517653 | Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma | not yet recruiting | Phase 2 | 70 | Shanghai Zhongshan HospitalOTHER | 0 | Apr 8, 2026 | clinicaltrials |
| NCT05289193 | CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma | active not recruiting | Phase 2 | 28 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT02816021 | Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma | completed | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05170334 | Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma | active not recruiting | Phase 2 | 7 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07511036 | PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma | not yet recruiting | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT06581406 | A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma | recruiting | Phase 2 / Phase 3 | 280 | Replimune, Inc.INDUSTRY | 3 | Apr 2, 2026 | clinicaltrials |
| NCT06295159 | Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma | recruiting | Phase 2 | 90 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT01840007 | Pilot Study Evaluating the Efficacy and Safety of Metformin in Melanoma | completed | Phase 2 | 20 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT05130177 | Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma | active not recruiting | Phase 2 | 8 | Diwakar DavarOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT07276386 | Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma | recruiting | Phase 2 | 18 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT07501104 | Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma(TRIUMPH-AM) | not yet recruiting | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 0 | Mar 30, 2026 | clinicaltrials |
| NCT03620019 | Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma | completed | Phase 2 | 25 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT02360579 | Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma(LN-144) | completed | Phase 2 | 220 | Iovance Biotherapeutics, Inc.INDUSTRY | 8 | Mar 25, 2026 | clinicaltrials |
| NCT07492121 | Screening for Brain Metastases(GAPIMET) | not yet recruiting | Phase 2 | 180 | University of ZurichOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT02723721 | Prospective Study of Ingenol Mebutate for Non-invasive Lentigo Melanoma of the Face(PICAMEL) | completed | Phase 2 | 20 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT06708455 | Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma | not yet recruiting | Phase 2 | 65 | Rapa Therapeutics LLCINDUSTRY | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04789668 | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases | terminated | Phase 1 / Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT03070392 | Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma | completed | Phase 2 | 378 | Immunocore LtdINDUSTRY | 14 | Mar 17, 2026 | clinicaltrials |
| NCT07477548 | A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies | not yet recruiting | Phase 2 | 67 | Yonsei UniversityOTHER | 0 | Mar 17, 2026 | clinicaltrials |
| NCT02068586 | Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma | active not recruiting | Phase 2 | 210 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT05907954 | (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma | active not recruiting | Phase 2 | 160 | IDEAYA BiosciencesINDUSTRY | 7 | Mar 16, 2026 | clinicaltrials |
| NCT00421317 | Imatinib in Adult Patients With Metastatic Ocular Melanoma(O-Mel-Inib) | terminated | Phase 2 | 13 | Centre Oscar LambretOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT04417621 | Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | active not recruiting | Phase 2 | 134 | Novartis PharmaceuticalsINDUSTRY | 12 | Mar 12, 2026 | clinicaltrials |
| NCT06223659 | EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers | recruiting | Phase 2 | 100 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT06771544 | Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma | recruiting | Phase 2 | 14 | University of California, IrvineOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT03999749 | A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma | active not recruiting | Phase 2 | 71 | NYU Langone HealthOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05926960 | A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma(PORTSIDE) | terminated | Phase 2 | 38 | PfizerINDUSTRY | 5 | Mar 9, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 13, 2026source: clinicaltrials